Phaseline

Targets › SGSH

SGSH (N-sulphoglucosamine sulphohydrolase): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Jun 2027.

Catalyzes a step in lysosomal heparan sulfate degradation. (UniProt, P51688)

Open in Phaseline: the race on SGSH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ultragenyx PharmaceuticalUX111
Self-complementary adeno-associated virus serotype 9 (scAAV9) carrying the human SGSH gene
SGSHPhase 2MPS IIIAMar 2029
GC BiopharmaGC1130A
Recombinant human heparan N-sulfatase (rhHNS)
SGSHPhase 1Sanfilippo Syndrome Type AJun 2027

Conditions

Sanfilippo Syndrome Type A (1) MPS IIIA (1)

Modalities

small molecule (1), mixed (1)

Companies

GC Biopharma (1) Ultragenyx Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.